GlaxoSmithKline Submits New Application for Synflorix in EU

GlaxoSmithKline said it has submitted a regulatory application in the European Union seeking approval of an additional indication for Synflorix, a paediatric pneumococcal vaccine, for the active immunization against pneumonia caused by Streptococcus pneumoniae in infants and children from 6 weeks up to 5 years of age.
Fox Business